BioNTech SE (FRA:22UA)

BioNTech SE Revenue

BioNTech SE had revenue of 145.80M EUR in the quarter ending June 30, 2026, a decrease of -56.99%. This brings the company's total for the last twelve months to 2.78B, down -3.41% year-over-year. In the year 2025, BioNTech SE had annual revenue of 3.05B with 5.63% growth.

• Revenue (ttm): 2.78B
• Revenue Growth: -3.41%
• P/S Ratio: 7.46
• Revenue / Employee: 339.44K
• Employees: 7,807
• Market Cap: 19.77B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• COVID-19 Vaccine 2.00B 65.3%
• Out-Licensing 613.00M 20.1%
• Other Sales 261.60M 8.6%
• Other 184.60M 6.0%

By Geography

• United States 1.79B 62.5%
• Germany 759.10M 26.5%
• Ireland 304.80M 10.6%
• Rest of The World 11.10M 0.4%

Fiscal year ended Dec 31, 2025 See the full BioNTech SE breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	3.05B	162.80M	5.63%
Dec 31, 2024	2.89B	-1.03B	-26.31%
Dec 31, 2023	3.92B	-13.39B	-77.33%
Dec 31, 2022	17.31B	-1.67B	-8.78%
Dec 31, 2021	18.98B	18.49B	3,834.63%
Dec 31, 2020	482.30M	373.70M	344.11%
Dec 31, 2019	108.60M	-18.98M	-14.87%
Dec 31, 2018	127.58M	65.98M	107.11%
Dec 31, 2017	61.60M	-	-

Data Sources: Fiscal.ai and S&P Global Market Intelligence Last updated: Jun 30, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company. Revenue geography data is provided by S&P Global Market Intelligence.

Update frequency:

Quarterly

Last checked:

Oct 21, 2026

Data Sources Report a data error